European Psychiatry
June 1, 2026
Agnieszka Mechlińska, Damian Swieczkowski, Aleksander Kwaśny et al.
Introduction MDMA (3,4-methylenedioxymethamphetamine)–assisted therapy has gained growing scientific attention as a potential treatment for post-traumatic stress disorder and other mental health conditions. Although clinical studies suggest potential benefits, concerns remain regarding cardiovascular safety, methodological rigor, and variability in psychotherapeutic support (Singh et al . CNS...
European Psychiatry
June 1, 2026
A. K. Sikora
Abstract Catatonia is a potentially life-threatening psychomotor syndrome that can complicate substance intoxication and may be missed in acute psychiatric and addiction settings. Synthetic cannabinoids (e.g., Spice/K2) are associated with severe neuropsychiatric presentations including agitation, psychosis, autonomic instability, and diagnostic ambiguity. This talk presents a clinical case of...
European Psychiatry
June 1, 2026
M. A. K. Guirguis, H. Raai
Introduction Auditory hallucinations are a debilitating manifestation of trauma in children. Voice-hearing is common among youth exposed to multiple traumatic experiences and is associated with cognitive mechanisms that contribute to the persistence of symptoms [1]. These experiences can cause severe distress, disrupt development, and may increase risk of self-harm mediated by hallucinatory...
European Psychiatry
June 1, 2026
N. Aguayo-Verdugo, N. Ulloa-Chamblás, R. Zúñiga-Tapia et al.
Introduction University students, particularly in health-related fields, face rising levels of stress, anxiety, and depression, which negatively affect academic performance, social engagement, and overall well-being. Post-pandemic challenges, such as social isolation, uncertainty, and abrupt transitions to online learning, have exacerbated these issues. Mindfulness-based interventions (MBIs)...
European Psychiatry
June 1, 2026
J. Völflová Motlová, M. Janoušková
Introduction Mindfulness can be defined as the ability to be aware of what is happening in the present moment, non-judgmentally. Active mindfulness training for mental healthcare professionals can lead to stress and anxiety reduction and, conversely, increase their empathy, trait mindfulness, and self-compassion. These attributes contribute to the prevention and reduction of burnout syndrome....
European Psychiatry
June 1, 2026
W. Aldulaimy, A. Shah
Introduction TBI patients often suffer from severe, treatment-resistant depression and PTSD. Ketamine shows promise in non-TBI populations, but its efficacy in TBI patients needs exploration for efficacy and tolerability. Objectives Evaluate ketamine’s clinical effectiveness and safety (PHQ-9, GAD-7, PCL-5 scores) in post-TBI patients, comparing IM, intranasal, and oral routes. Methods Design:...
European Psychiatry
June 1, 2026
A. Rami
Introduction Suicidal crisis represents a major psychiatric emergency, often occurring in the context of mood disorders and requiring rapid, effective interventions. Traditional antidepressant treatments usually have a delayed onset of action, underscoring the need for fast-acting therapeutic alternatives. In recent years, ketamine—an NMDA receptor antagonist—has emerged as a promising option...
European Psychiatry
June 1, 2026
S. Joowong, P. Tansupasiri
Introduction Following Thailand’s cannabis decriminalization in 2022, a marked rise in psychiatric presentations related to cannabis use has been observed nationwide. While international evidence has linked high-THC cannabis exposure to psychosis and substance-induced disorders, empirical data from Asian settings remain limited. This late-breaking study provides updated national trends and...
European Psychiatry
June 1, 2026
A. Kuzma-Hunt, Z. Hamadeh, V. Tsang
Introduction Ketamine-assisted therapy shows rapid benefit in treatment-resistant depression, anxiety, and PTSD (Walsh et al. BJPsych Open 2022;8:e19). The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a unique 12-week program that combines 12 Community of Practice (group therapy) sessions and three ketamine medicine sessions (Tsang et al. Ther Adv Psychopharmacol...
European Psychiatry
June 1, 2026
S. Gupta
Introduction Cannabis consumption has rapidly increased in Delaware due to the legalization of recreational use. There is limited research, however, investigating the links between cannabis use and cognition in older adults. Objectives The objective of this study is to represent the first population-level analysis of cannabis use and subjective cognitive decline (SCD) in older adults in First...
European Psychiatry
June 1, 2026
J. Chapelas, L. Costa, M. Alves et al.
Introduction The expanding use of cannabis, in both recreational and medicinal contexts, highlights a dual reality of therapeutic potential and clinical concern. On one side, cannabinoids show promising medical applications, including chronic pain relief and antiemetic effects. On the other, cannabis consumption is linked to a broad spectrum of adverse outcomes. Psychiatric effects range from...
European Psychiatry
June 1, 2026
T. Jendričko, N. Sutara, A. Matić et al.
Introduction Maladaptive Daydreaming (MD) is a relatively new and still under-recognized phenomenon. It is characterized by prolonged and emotionally engaging immersion in highly structured fantasies. Unlike normal daydreaming, MD involves narrative scenarios with complex characters and plots that may extend into real life. Individuals often spend hours per day in such fantasies, typically...
European Psychiatry
June 1, 2026
V. Sharma, S. Ather, A. Sič et al.
Introduction Suicide is a leading cause of death in the psychiatric population. The existing modes of treatment (pharmacological and psychotherapeutic) for suicidality are effective but have longer onset, this delay causing a dangerous therapeutic gap in an acute crisis. We compare the two fast-acting treatments, the newer psychopharmacological agent Ketamine and well-established...
European Psychiatry
June 1, 2026
Miriam Olivola, V. Martiadis, Kevin la Monica et al.
Introduction The role of dissociation in mediating antidepressant response to intranasal esketamine remains debated. While dissociative experiences are often observed during treatment, their predictive value for clinical outcomes is uncertain. Objectives We aimed to assess whether (i) baseline dissociative traits (DES-II) and (ii) early changes in dissociation (ΔDES T0→T2) predict short-term...
European Psychiatry
June 1, 2026
L. Jishkariani, D. Zurabashvili, K. Gigolashvili et al.
Introduction Cannabis decriminalization raises concerns about its psychiatric impact, particularly on psychosis risk. As cannabis became decriminalized in Georgia in 2018, questions emerged regarding changes in substance-related and acute psychotic disorders. Examining these trends is essential to guide prevention, treatment, and policy in a shifting drug landscape. Objectives This study aims...
European Psychiatry
June 1, 2026
J. Tripp, G. Smagin
Introduction MM120 (lysergide D-tartrate, LSD, CAS 32426-57-6) is under development as a potential treatment for generalized anxiety disorder and major depressive disorder. MM120 may elicit profound lasting psychological changes through interaction with brain 5-HT1A, 1B, 2A, 2C, 6 and 7 receptors, among others, while the complete mechanism is not clear. Objectives The study was performed to...
European Psychiatry
June 1, 2026
Giada Versaci, Miriam Olivola, Kevin la Monica et al.
Introduction Esketamine-induced dissociation is a transient, pharmacologically mediated alteration in consciousness, often distinct from pathological dissociation. While not required for clinical improvement, these states may engage neural circuits implicated in therapeutic change. Objectives This study explores patients’ lived experiences of dissociation as potentially meaningful transitional...
European Psychiatry
June 1, 2026
I. C. Mândraș, A. L. Comșa
Introduction Suicidality represents a major clinical and public health challenge, particularly among patients with treatment-resistant depression (TRD), who carry a disproportionately high risk of suicide. Traditional antidepressants often have delayed onset and limited efficacy in reducing suicidal ideation in this high-risk population, highlighting the need for rapid-acting interventions....
European Psychiatry
June 1, 2026
Lewis Mehl‐Madrona, Barbara Mainguy
Introduction Creative arts therapies, particularly drama therapy techniques, are useful in psychotherapy Objectives We aim to show how the creative arts can be used in the treatment of psychosis and in training people about the experience of psychosis. Methods The techniques can be used in one-on-one appointments or in groups. Useful approaches include the client’s making figures to represent...
European Psychiatry
June 1, 2026
R. Szegedi, F. Mónus, Á. Bernáth et al.
Introduction Eco-anxiety—though not a formal diagnosis—captures climate-related distress overlapping with anxiety-spectrum processes. While mindfulness is often framed as protective, facet-level links to eco-anxiety are underexplored in Central/Eastern Europe. Ecological connectedness may also heighten sensitivity to environmental threat. We examined how mindfulness facets and nature...
European Psychiatry
February 13, 2026
Haining Ma, Huaigui Liu, Wenwei Zhang et al.
Considerable effort has been devoted to investigate the neuroimaging correlates and predictors of antidepressant response to ketamine, yet inconsistency in the location and nature of the regional brain effects makes it difficult to unify this research. Despite the revolutionary notion that psychiatric therapeutics show network-level brain representations, investigations into network...
European Psychiatry
2026
Andy Lu, Heidi Xu, Gia Han Le et al.
4 citations
The reported mixed findings suggest that the opioid system may exert a partial mediating effect of ketamine in TRD. However, given the inconsistent attenuation of ketamine's antidepressant effects by opioid receptor antagonists, the opioid system likely functions as a context-dependent modulator rather than a primary mediator, particularly at standard antidepressant doses.
European Psychiatry
2026
Shakila Meshkat, Qiaowei Lin, Rachel Sousa-Ho et al.
Abstract Background Psychedelic-assisted psychotherapy has shown potential for psychiatric disorders. However, the magnitude of symptom change in control groups remains poorly understood. We aim to evaluate within-group effects in control groups and compare them to treatment groups in psychedelic trials. Methods A systematic search was conducted up to 1 July 2025. The study protocol was...
European Psychiatry
October 14, 2025
Andreas Reif, Bernhard T Baune, Jozefien Buyze et al.
Clinical response and remission may not fully reflect patient priorities in treatment-resistant depression (TRD). Health-related quality-of-life (HRQoL) outcomes should be assessed to comprehensively capture treatment benefits. ESCAPE-TRD (NCT04338321) was a 32-week randomized, phase IIIb trial comparing esketamine nasal spray (NS) versus quetiapine extended release (XR), both alongside an...
European Psychiatry
August 26, 2025
Ismaël Conejero, Raquel Alvarez García, Alejandro Porras-Segovia et al.
2 citations
Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We evaluated the factors associated with achieving remission in these individuals. The study was carried out across four psychiatry departments in Madrid, Spain. Patients aged over 18 years were included if they received esketamine as an augmentation treatment for TRD....